Current Practices for U.S. Newborn Screening of Pompe Disease and MPSI

Abstract

by Elizabeth G. Ames,Rachel Fisher,Mary Kleyn andAyesha Ahmad
Int. J. Neonatal Screen. 2020, 6(3), 72; https://doi.org/10.3390/ijns6030072 - 15 FEB 2022
Cited by 14 | Viewed by 3418
Abstract
Two lysosomal storage disorders (LSDs), Pompe disease and Mucopolysaccharidosis type I (MPSI) were added to the Recommended Uniform Screening Panel (RUSP) for newborn screening (NBS) in 2015 and 2016, respectively. These conditions are being screened with variable practice in terms of primary and reflex analytes (either biochemical or molecular testing) as well as collection of short- and long-term follow-up elements. The goal of this study is to evaluate practices of state health departments in regards to screening methods and follow-up data collected. We conducted online surveys and phone questionnaires to determine each U.S. state’s practices for screening and follow-up of positive newborn screens. We report the first snapshot of practices for NBS for the LSDs included on the RUSP. All 50 U.S. states responded to our survey. The majority of U.S. states are not currently screening for Pompe disease and MPSI as of March 2020, but this number will increase to 38 states in the coming 1–3 years based on survey results. Our survey identifies data elements used by state health departments for short-and long-term follow-up that could serve as the basis of common elements for larger, public health-based analyses of the benefits and efficacy of screening for Pompe disease and MPSI. Full article
► Show Figures
7 pages, 675 KiB
Open AccessArticle